Can new treatment help patients ditch harmful steroids?
NCT ID NCT07221838
Summary
This study aims to see if adults with generalized myasthenia gravis who are already receiving ravulizumab treatment can safely reduce or stop their steroid medications. Researchers will follow 75 participants as they follow a planned steroid reduction schedule while monitoring their muscle weakness symptoms. The goal is to help patients avoid the long-term side effects of steroids while keeping their myasthenia gravis under control.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
Chicago, Illinois, 60637, United States
-
Research Site
Schaumburg, Illinois, 60173, United States
-
Research Site
Neptune City, New Jersey, 07753, United States
-
Research Site
Raleigh, North Carolina, 27607, United States
-
Research Site
Knoxville, Tennessee, 37920, United States
-
Research Site
Bochum, 44789, Germany
-
Research Site
Milan, 20122, Italy
-
Research Site
Naples, 80131, Italy
-
Research Site
Rome, 00189, Italy
-
Research Site
Ibaraki, 305-8576, Japan
-
Research Site
Kitakyushu-shi, 807-8555, Japan
-
Research Site
Kumamoto, 860-8556, Japan
Conditions
Explore the condition pages connected to this study.